CH EPL (R5), published by Federal Office of Public Health FOPH. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ci-build built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/bag-epl/bag-epl-fhir/ and changes regularly. See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:RegulatedAuthorization ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "MA-67431001"] ; #
fhir:meta [
( fhir:profile [
fhir:v "http://fhir.ch/ig/ch-epl/StructureDefinition/ch-idmp-regulatedauthorization"^^xsd:anyURI ;
fhir:link <http://fhir.ch/ig/ch-epl/StructureDefinition/ch-idmp-regulatedauthorization> ] )
] ; #
fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: RegulatedAuthorization MA-67431001</b></p><a name=\"MA-67431001\"> </a><a name=\"hcMA-67431001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-ch-idmp-regulatedauthorization.html\">IDMP RegulatedAuthorization</a></p></div><p><b>identifier</b>: <code>http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-MarketingAuthorisationNumber</code>/67431001</p><p><b>subject</b>: <a href=\"MedicinalProductDefinition-Triogen-250mg-Capsule.html\">MedicinalProductDefinition: extension = Capsule, hard,TRIOGEN wird vergütet zur Behandlung der Kupferspeicherkrankheit (Morbus Wilson) bei Patienten, die eine Behandlung mit D-Penicillamin nicht vertragen. Die Behandlung muss von Gastroenterologen oder Hepatologen mit Erfahrung bei der Behandlung von Patienten mit Morbus Wilson initiiert und überwacht werden.; identifier = http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-MPID#CH-7601001403062-6743101; indication = Zur Behandlung der Kupferspeicherkrankheit (Morbus Wilson) bei Patienten, die eine Behandlung mit D-Penicillamin nicht vertragen.; legalStatusOfSupply = Medicinal product subject to medical or veterinary prescription (B); additionalMonitoringIndicator = No Warning; pediatricUseIndicator = Authorised for the treatment in children; classification = trientine,NA KAS art. 12 para. 5 TPLO,Synthetic,Originator product</a></p><p><b>type</b>: <span title=\"Codes:{http://fhir.ch/ig/ch-epl/CodeSystem/ch-authorisation-type 756000002001}\">Marketing Authorisation</span></p><p><b>region</b>: <span title=\"Codes:{urn:iso:std:iso:3166 CH}\">Switzerland</span></p><p><b>status</b>: <span title=\"Codes:{http://fhir.ch/ig/ch-epl/CodeSystem/ch-SMC-authorisation-status 756005023007}\">valid</span></p><p><b>statusDate</b>: 2020-05-28</p><p><b>holder</b>: <a href=\"#hcMA-67431001/holder-Ideogen-AG\">Organization IDEOGEN AG</a></p><p><b>regulator</b>: <a href=\"#hcMA-67431001/regulator-SMC\">Organization SMC</a></p><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Organization #holder-Ideogen-AG</b></p><a name=\"MA-67431001/holder-Ideogen-AG\"> </a><a name=\"hcMA-67431001/holder-Ideogen-AG\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-ch-epl-organization.html\">CH EPL Organization</a></p></div><p><b>identifier</b>: <a href=\"NamingSystem-LOC.html\" title=\"Identifier holding a number for LocID (Location Identifier of the European Medicines Agency - Organisation Management System OMS)\">LOC Identifier</a>/100012910, <a href=\"NamingSystem-GLN.html\" title=\"Identifier holding a number for GLN (Global Location Number)\">GLN Identifier</a>/7601001403062</p><p><b>name</b>: IDEOGEN AG</p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Organization #regulator-SMC</b></p><a name=\"MA-67431001/regulator-SMC\"> </a><a name=\"hcMA-67431001/regulator-SMC\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-ch-epl-organization.html\">CH EPL Organization</a></p></div><p><b>identifier</b>: <a href=\"NamingSystem-LOC.html\" title=\"Identifier holding a number for LocID (Location Identifier of the European Medicines Agency - Organisation Management System OMS)\">LOC Identifier</a>/100010911, <a href=\"NamingSystem-GLN.html\" title=\"Identifier holding a number for GLN (Global Location Number)\">GLN Identifier</a>/7601001398511</p><p><b>name</b>: SMC</p></blockquote></div>"^^rdf:XMLLiteral
] ; #
fhir:contained ( [
a fhir:Organization ;
fhir:id [ fhir:v "holder-Ideogen-AG" ] ;
fhir:meta [
( fhir:profile [
fhir:v "http://fhir.ch/ig/ch-epl/StructureDefinition/ch-epl-organization"^^xsd:anyURI ;
fhir:link <http://fhir.ch/ig/ch-epl/StructureDefinition/ch-epl-organization> ] ) ] ;
( fhir:identifier [
fhir:system [ fhir:v "urn:oid:1.2.276.0.76"^^xsd:anyURI ] ;
fhir:value [ fhir:v "100012910" ] ] [
fhir:system [ fhir:v "urn:oid:2.51.1.3"^^xsd:anyURI ] ;
fhir:value [ fhir:v "7601001403062" ] ] ) ;
fhir:name [ fhir:v "IDEOGEN AG" ]
] [
a fhir:Organization ;
fhir:id [ fhir:v "regulator-SMC" ] ;
fhir:meta [
( fhir:profile [
fhir:v "http://fhir.ch/ig/ch-epl/StructureDefinition/ch-epl-organization"^^xsd:anyURI ;
fhir:link <http://fhir.ch/ig/ch-epl/StructureDefinition/ch-epl-organization> ] ) ] ;
( fhir:identifier [
fhir:system [ fhir:v "urn:oid:1.2.276.0.76"^^xsd:anyURI ] ;
fhir:value [ fhir:v "100010911" ] ] [
fhir:system [ fhir:v "urn:oid:2.51.1.3"^^xsd:anyURI ] ;
fhir:value [ fhir:v "7601001398511" ] ] ) ;
fhir:name [ fhir:v "SMC" ]
] ) ; #
fhir:identifier ( [
fhir:system [ fhir:v "http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-MarketingAuthorisationNumber"^^xsd:anyURI ] ;
fhir:value [ fhir:v "67431001" ]
] ) ; #
fhir:subject ( [
fhir:reference [ fhir:v "MedicinalProductDefinition/Triogen-250mg-Capsule" ]
] ) ; #
fhir:type [
( fhir:coding [
fhir:system [ fhir:v "http://fhir.ch/ig/ch-epl/CodeSystem/ch-authorisation-type"^^xsd:anyURI ] ;
fhir:code [ fhir:v "756000002001" ] ;
fhir:display [ fhir:v "Marketing Authorisation" ] ] )
] ; #
fhir:region ( [
( fhir:coding [
fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ;
fhir:code [ fhir:v "CH" ] ;
fhir:display [ fhir:v "Switzerland" ] ] )
] ) ; #
fhir:status [
( fhir:coding [
fhir:system [ fhir:v "http://fhir.ch/ig/ch-epl/CodeSystem/ch-SMC-authorisation-status"^^xsd:anyURI ] ;
fhir:code [ fhir:v "756005023007" ] ;
fhir:display [ fhir:v "valid" ] ] )
] ; #
fhir:statusDate [ fhir:v "2020-05-28"^^xsd:date] ; #
fhir:holder [
fhir:reference [ fhir:v "#holder-Ideogen-AG" ]
] ; #
fhir:regulator [
fhir:reference [ fhir:v "#regulator-SMC" ]
] . #
IG © 2023+ Federal Office of Public Health FOPH. Package ch.fhir.ig.ch-epl#1.0.0-ci-build based on FHIR 5.0.0. Generated 2025-09-01
Links: Table of Contents |
QA Report
| Propose a change